Bioharvest Sciences Earnings Call Highlights Growth Momentum

Bioharvest Sciences, Inc. ((BHST)) has held its Q4 earnings call. Read on for the main highlights of the call.

Bioharvest Sciences, Inc. struck an upbeat tone on its latest earnings call, emphasizing strong revenue growth, expanding margins, and a dramatically fortified cash position. Management balanced this optimism with realism about ongoing GAAP losses, heavy marketing and CDMO investment, and geopolitical risks, but argued that operational momentum and product traction set up a favorable multi‑year trajectory.

Top-Line Growth Remains Robust

Bioharvest reported Q4 2025 revenue of $9.1 million, up 25% year over year, underscoring sustained demand momentum. Full-year 2025 revenue climbed 37% to $34.5 million, highlighting the company’s ability to grow off a larger base while expanding its product and channel footprint.

Margins Improve and EBITDA Turns Positive

Profitability metrics moved in the right direction as Q4 gross profit rose 27% to $5.2 million, lifting gross margin to 58%, up 100 basis points from last year. For 2025, gross margin reached 59%, a 400 basis-point improvement, and adjusted EBITDA turned positive at $0.5 million in Q4 versus a $1.8 million loss in the prior-year quarter.

Balance Sheet Strengthened by Cash Build

The company ended 2025 with $23.0 million in cash and cash equivalents, a massive jump from $2.4 million a year earlier. Management highlighted this roughly ninefold increase as critical fuel for 2026 investments in marketing, CDMO capacity, and product innovation without immediately relying on fresh external capital.

VINIA D2C Engine Drives U.S. Leadership

The VINIA direct-to-consumer franchise continued to power results, generating $30.6 million in U.S. revenue for 2025 and cementing its position as the leading resveratrol polyphenol brand. The company cited Nielsen IQ and Amazon data plus a growing base of more than 85,000 active users as of March 2026 to argue that VINIA now holds clear market leadership.

New VINIA BloodFlow Hydration Launch Gains Traction

Launched in early December, VINIA BloodFlow Hydration quickly became the second-largest driver of incremental new-customer sales, contributing about 15% of year-to-date new-customer revenue on the company’s website. The product is also commanding roughly a 50% price premium to market leaders, backed by strong early reviews on both vinia.com and Amazon and over 1,300 participants in a consumer challenge.

Operating Leverage Shows Early Signs of Scale

Operating expenses rose in absolute terms to $6.3 million in Q4 from $5.8 million a year ago as the company invested in marketing and CDMO capabilities. Yet those expenses fell to 70% of revenue from 80%, signaling improving operating leverage as higher sales increasingly absorb the fixed and semi-fixed cost base.

CDMO Breakthroughs Enhance Scientific Credibility

The CDMO division reported a notable milestone by completing Stage 1 development for a rare, endangered fragrance plant using cell culture while retaining an economic stake in the compositions. Management also cited progress in pharma, saffron, and nutrition programs, along with internal assets like pomegranate and blueberry polyphenols, positioning the pipeline as increasingly de-risked.

CDMO Revenue Ambitions Point to Acceleration

Third-party CDMO revenue was about $2 million in 2025, but management framed this as a base from which external CDMO sales could climb to $4–6 million in 2026. Including internal manufacturing, 2025 CDMO-related activity was closer to $9 million, and the company sees a path to meaningful acceleration as current programs advance toward manufacturing phases.

Digital-First Go-to-Market Strategy Evolves

Bioharvest continues to pivot its marketing mix from traditional TV toward digital channels such as Facebook, Instagram, YouTube, and TikTok to sharpen customer targeting. In parallel, a growing Health Pros channel of roughly 250 partners, which is expanding by 25–50 per month, already delivered more than 10% of incremental new-customer revenue in March, broadening reach and demographics.

Net Loss Highlights Growth-Investment Trade-Off

Despite improving metrics, the company remains in the red, posting a Q4 2025 net loss of $2.2 million, or $0.10 per share, versus a $3.0 million loss a year earlier. Management acknowledged that ongoing marketing and CDMO investments will keep near-term GAAP profitability under pressure even as adjusted results trend more favorably.

Higher Operating Spend Supports Expansion

Absolute operating expenses increased to $6.3 million in Q4 from $5.8 million, reflecting elevated marketing efforts and CDMO development costs. Executives framed this rising spend as deliberate, aimed at capturing share in the premium wellness category and building a differentiated cell-based manufacturing platform for later, higher-margin revenue.

CDMO Revenue Still Modest and Volatile

Management cautioned that the CDMO business remains in its early stages, with about $2 million in third-party revenue and inherently long development cycles. Typical programs span 18–27 months and can range from $2–3 million, especially in pharma, making quarterly revenue recognition lumpy and timing of larger manufacturing contracts uncertain.

Channel Concentration Presents Execution Risk

The company’s revenue base remains heavily concentrated in its own website, which accounts for roughly 80% of sales and is dominated by subscription customers. Amazon represents the remaining 20%, so the shift from TV to digital advertising and any disruption to the subscription engine could introduce volatility while Bioharvest fine-tunes its marketing mix.

Geopolitical Tension and Supply Chain Watchpoints

Management flagged the conflict in the Middle East as a continuing external risk, with previous airspace closures and flight disruptions already experienced. While operations and research remain uninterrupted and cargo routes have resumed, the company is monitoring potential supply chain volatility that could affect logistics and delivery times.

Marketing Intensity May Temper Near-Term Margins

Sales and marketing continue to be a major expense category, historically approaching the mid-40% range as a share of sales. With increased spending on digital channels and Health Pros, management signaled that margin gains may be gradual until acquisition efficiencies deepen and lifetime-value trends fully justify the elevated customer acquisition costs.

Longer Path to Commercial Manufacturing Scale

For the headline fragrance program, the company expects pre-commercial biomass for testing within 6–9 months and industrial-scale manufacturing roughly 12–18 months later. That timeline implies that substantial manufacturing revenue from such CDMO projects is more likely to emerge from late 2027 onward, underscoring the medium-term nature of this growth pillar.

Guidance Signals Nonlinear Growth and 2026 Profit Goals

Looking ahead, management expects the VINIA direct-to-consumer business to reach profitability in 2026 and is targeting $4–6 million in external CDMO revenue for the year. They described 2026 revenue growth as nonlinear, with a softer first quarter followed by accelerating momentum through the rest of the year, and aim for steady gross-margin expansion toward the mid-60% range over time.

Bioharvest’s earnings call painted a picture of a company transitioning from early-stage builder to scaling operator, with VINIA driving near-term growth and CDMO offering longer-dated upside. Investors will need to weigh continued losses, channel and geopolitical risks, and long CDMO timelines against solid revenue growth, improving margins, and a strengthened balance sheet that underpins an overall constructive outlook.